Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19

13Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

The COVID-19 pandemic has had a deep impact on people worldwide since late 2019 when SARS-CoV-2 was first identified in Wuhan, China. In addition to its effect on public health, it has affected humans in various aspects of life, including social, economic, cultural, and political. It is also true that researchers have made vigorous efforts to overcome COVID-19 throughout the world, but they still have a long way to go. Accordingly, innumerable therapeutics and vaccine candidates have been studied for their efficacies and have been tried clinically in a very short span of time. For example, the versatility of extracellular vesicles, which are membrane-bound particles released from all types of cells, have recently been highlighted in terms of their effectiveness, biocompatibility, and safety in the fight against COVID-19. Thus, here, we tried to explain the use of extracellular vesicles as therapeutics and for the development of vaccines against COVID-19. Along with the mechanisms and a comprehensive background of their application in trapping the coronavirus or controlling the cytokine storm, we also discuss the obstacles to the clinical use of extracellular vesicles and how these could be resolved in the future.

Cite

CITATION STYLE

APA

Mustajab, T., Kwamboka, M. S., Choi, D. A., Kang, D. W., Kim, J., Han, K. R., … Chwae, Y. J. (2022, October 1). Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms231911247

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free